Clinical Trials Browser

Completed × OTHER × Paraganglioma, Extra-Adrenal × Clear all

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Phase 2 Completed

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Phase NA Completed

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Phase 2 Completed

3 enrolled 9 charts

Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05858177 2023-05-15

MPPGL

Phase 2 Completed

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01155258 2016-06-13

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1 Completed

BreastCNSDermatologicEndocrineGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Paraganglioma, Extra-Adrenal, Pheochromocytoma, Prostatic Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT01152827 2015-05-20

PheoCarcRAD001

Phase 2 Completed

Paraganglioma, Extra-Adrenal, Pheochromocytoma